Interestingly, a recent study showed that melanoma cell lines resistant to a BRAF inhibitor (PLX4032) display increased CDC42 activity compared to non-resistant melanoma cells (Mohapatra et al., 2019) (Table 1). This evidence concerns the gene BRAF and melanoma.